About: Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
Creator	Ye, Jing Xu, Jianqing Liu, Meiqin Shi, Zhengli Lu, Xiao Sun, Bing Yang, Zhuo Sun, Xiaoyu Ling, Zhiyang Ding, Longfei Gu, Wangpeng Ma, Liyang Qu, Aidong Yi, Chunyan Zhang, Yaguang
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1038/s41423-020-0458-z
bibo:pmid	32415260
has license	cc-by
sha1sum (hex)	1aecdcf88e00ccc75348f755ef9b75fc1961d68d
schema:url	https://doi.org/10.1038/s41423-020-0458-z
resource representing a document's title	Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
has PubMed Central identifier	PMC7227451
has PubMed identifier	32415260
schema:publication	Cell Mol Immunol
resource representing a document's body	covid:1aecdcf88e00ccc75348f755ef9b75fc1961d68d#body_text
is schema:about of	named entity 'COVID-19' named entity 'human' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'neutralizing antibodies' named entity 'residues' named entity 'mice' named entity 'drugs' named entity 'coronavirus' named entity 'receptor' named entity 'RBD' named entity 'develop' named entity 'prophylactic' named entity 'This' named entity 'interact' named entity 'SARS-CoV' named entity 'ACE2' named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'interact' named entity 'neutralizing antibodies' named entity 'angiotensin-converting enzyme 2' named entity 'human coronavirus' named entity 'SARS-CoV-2' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'epitope' named entity 'immunization' named entity 'antigenic' named entity 'Coronavirus disease 2019' named entity 'receptor binding' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'induce' named entity 'neutralizing antibodies' named entity 'SARS-CoV' named entity 'dissociation constant' named entity 'RBD' named entity 'vaccine' named entity 'A475' named entity 'protein' named entity 'RBD' named entity 'SARS-CoV' named entity '293T cells' named entity 'mAbs' named entity 'RBD' named entity 'SARS-CoV' named entity 'streptomycin' named entity 'antibodies' named entity 'COVID' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'convergent evolution' named entity 'hACE2' named entity 'SARS' named entity 'SARS' named entity 'evolution' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'RBMs' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software